FDA
-
-
-
-
-
-
-
UCB to acquire Neurona Therapeutics, advancing its innovative leadership in epilepsy through regenerative science
-
-
-
-
-
-
-
/C O R R E C T I O N -- UCB/
-
-
-
-
-
-
-
UCB presents latest research across leading neurology portfolio at American Academy of Neurology (AAN) meeting 2025
-
-
-
-
-
-
-
UCB presents latest scientific research in epilepsy at American Epilepsy Society (AES) Annual Meeting
-
-
-
-
-
-
-
UCB presents new data highlighting developments across expansive neurology portfolio at 76th American Academy of Neurology (AAN) Annual Meeting
-
-
-
-
-
-
-
UCB presents latest data from generalized myasthenia gravis portfolio at 2023 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Founda
-
-
-
-
-
-
-
UCB announces U.S. availability of RYSTIGGO® (rozanolixizumab-noli) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscl
-
330,677 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

